MedTrace Logo

Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen

NCT01705873 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2012-10-12

No results posted yet for this study

Summary

The objective of this study is to evaluate changes in Framingham score (from low to moderate, from moderate to high) based on changes in lipid profile and other parameters from baseline to 48 weeks of HAART in naïve patients or patients in second line of treatment, considering LPV/r vs EFV based HAART. The null hyphotesis is that there is an increased Framingham score in patients treated with LPV/r as second line treatment and in patients treated with LPV/r or EFV regimen as first line treatments.

Conditions

Sponsors & Collaborators

  • Abbott

    collaborator INDUSTRY

  • Helios Salud

    lead OTHER

Principal Investigators

  • Lidia I Cassetti, MD · Helios Salud

  • Diego M Cecchini, PhD · Helios Salud

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2013-03-31
Completion
2013-08-31

Countries

  • Argentina

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01705873 on ClinicalTrials.gov